Bayer's Mirena Gets Approval In Europe For Extended Duration Of Use In Contraception

RTTNews | 874日前

(RTTNews) - German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Friday that Mirena (52mg LNG IUS), its long-acting reversible intrauterine system, received regulatory approval in the European Workshare Procedure for up to eight years in contraception. This is the longest contraceptive duration of use for any hormonal intrauterine system.

The levonorgestrel (LNG) releasing intrauterine system (IUS) Mirena has been approved for countries in Europe.

This regulatory approval in Europe is based on the results of the Mirena Extension Trial evaluating the efficacy and safety of Mirena which demonstrated that contraceptive efficacy remains high with greater than 99% during years six to eight of use.

Following the completion of the European Workshare procedure the first national approvals in the EU are expected in the fourth quarter of 2022.

The European approval also includes symptom driven extended use for the indication idiopathic menorrhagia (heavy menstrual bleeding) for up to eight years or until symptoms return.

In August 2022, Bayer received U.S. approval for the extended duration of use for up to eight years in the contraception indication for its levonorgestrel (LNG) releasing intrauterine system (IUS) Mirena.

A LNG-IUS is one of the most effective birth control methods as it does not require user compliance such as daily dosing or monthly re-fills. It can be removed by the doctor at any time.

For More Such Health News, visit rttnews.com

Bayer Stock Up On Growth View Starting FY26, Despite Q4 Loss, Cautious FY25

Shares of Bayer AG were gaining around 6 percent in the German trading after the pharmaceutical and life sciences major Wednesday said it expects improved performance from 2026 onwards, despite reporting a slip to loss in its fourth quarter. The company also projects weak core earnings and nearly flat sales for fiscal 2025.

RTTNews | 1日前

Bayer Stock Slips On Q3 Loss, Cautious Outlook

Shares of Bayer AG were losing around 11 percent in the morning trading on Germany's XETRA after the pharmaceutical and life sciences major reported Tuesday loss in its third quarter and weak adjusted EBITDA, amid nearly flat sales. The net loss, however, was narrower than last year, while EBIT loss widened. Further, the company trimmed its fiscal 2024 adjusted EBITDA forecast for the group...

RTTNews | 114日前

Bayer Submits SNDA For Expanded Use Of NUBEQA In Metastatic Hormone-Sensitive Prostate Cancer To FDA

German pharmaceutical company Bayer AG (BAYZF.PK, BAYRY.PK, BYR.L) announced Thursday the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibitor (ARi) NUBEQA (darolutamide) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

RTTNews | 161日前

Bayer Stock Climbs On US Legal Win In Roundup Cancer Claims

Shares of Bayer AG were climbing around 11 percent in German trading after the pharmaceutical and life sciences major announced a favorable ruling in the United States in the lawsuit over cancer claims against its Roundup weed killer. In a statement, the company noted that the Third Circuit Court of Appeals issued its favorable ruling in Schaffner v. Monsanto...

RTTNews | 202日前

Bayer Q4 Profit Surges, Warns On FY24; Says Break-up Not Now

German pharmaceutical and biotechnology major Bayer AG reported Tuesday a surge in its fourth-quarter net profit benefited by weak expenses. Meanwhile, sales were hurt by lower Pharmaceuticals sales, despite growth in Crop Science and consumer Health segments. Further, the company trimmed its dividend, and said it sees lower adjusted earnings and nearly flat sales in fiscal 2024 on a currency-adju

RTTNews | 366日前

Eurozone Retail Sales Fall Unexpectedly

Eurozone retail sales declined unexpectedly in January on non-food and auto fuel sales, official data showed on Thursday. Retail sales registered a monthly drop of 0.3 percent, confounding expectations for an increase of 0.1 percent. The statistical office revised up retail sales for December to nil growth from the initial estimate of 0.2 percent fall.

RTTNews | 5時7分前

Turkey Central Bank Slashes Rate By 250 Bps

Turkey's central bank lowered its benchmark rate for the third straight time on Thursday as the underlying trend of inflation softened. The Monetary Policy Committee, headed by Yasar Fatih Karahan, decided to reduce the policy rate to 42.5 percent from 45.0 percent, as widely expected. The bank had reduced the rate by 250 basis points each in December and January.

RTTNews | 5時46分前

Air France-KLM Stock Climbs On Narrower Q4 Loss, Positive Outlook

Shares of Air France-KLM Group were gaining more than 20 percent in the morning trade in Paris after the airline reported Thursday narrower net loss and significantly higher EBITDA, a key earnings metric, in its fourth quarter amid good growth in passenger traffic, capacity and load factor. Further, the company projects capacity growth in fiscal 2025, and maintained medium term outlook.

RTTNews | 6時33分前

EURUSD	1.0816	GBPUSD	1.28846	AUDUSD	0.63402
USDJPY	147.575	USDCAD	1.4359	USDCHF	0.88602

Advertisement

Bayer's Mirena Gets Approval In Europe For Extended Duration Of Use In Contraception